Immune clues in childhood leukemia: new study measures key cytokines
NCT ID NCT07509385
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure two immune proteins, IL-17A and IL-10, in the blood of 80 people newly diagnosed with B-cell acute lymphoblastic leukemia. Researchers want to see if these levels are linked to lab results and how well patients respond to treatment. The goal is to learn more about the disease, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand how certain immune signals relate to leukemia activity and treatment response.
- What could go wrong
- This is an early observational study with only 80 participants. It measures biological markers, not a treatment, so it won't directly improve outcomes. Results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.